copolymer 1 (glatiramer acetate)

Israeli drug (Teva Pharmaceutical); a synthetic polypeptide consisting of L-Ala, L-Glu, L-Lys, and L-Tyr; produces antigen-suppressor cells specific for myelin-based protein; potential drug for treating multiple sclerosis; TV-5010 has a molecular weight of 15-kDa

Also Known As:

Networked: 744 relevant articles (92 outcomes, 147 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Arnon, Ruth: 19 articles (04/2014 - 05/2002)
2.	Aharoni, Rina: 19 articles (04/2014 - 05/2002)
3.	Comi, Giancarlo: 13 articles (11/2015 - 11/2002)
4.	Wolinsky, J S: 13 articles (04/2011 - 01/2000)
5.	Zamvil, Scott S: 12 articles (12/2015 - 09/2002)
6.	Comi, G: 12 articles (07/2013 - 06/2000)
7.	Ziemssen, Tjalf: 11 articles (09/2015 - 11/2002)
8.	Filippi, Massimo: 11 articles (01/2015 - 08/2003)
9.	Sela, Michael: 11 articles (04/2014 - 05/2002)
10.	Trojano, Maria: 10 articles (11/2015 - 01/2007)

Related Diseases

1.	Multiple Sclerosis 08/01/2000 - "This study demonstrates the sustained efficacy of glatiramer acetate in reducing the relapse rate and in slowing the accumulation of disability in patients with relapsing forms of multiple sclerosis. " 02/01/2009 - "The cumulative evidence for the long-term clinical efficacy of glatiramer acetate is consistent with its dual mechanism of action, reassures the physician that glatiramer acetate can really help improve patient care over the long term, and may contribute to a more positive view of prognosis for patients with multiple sclerosis." 07/01/2013 - "The placebo-controlled phase of the PreCISe study showed that glatiramer acetate delayed onset of clinically definite multiple sclerosis (CDMS) in patients with clinically isolated syndrome and brain lesions on MRI. " 01/01/2010 - "A study included 158 patients stratified into 3 groups: 57 patients with multiple sclerosis (MS) of the main group who were treated with copaxone in dosage 20 mg/d during 4,3±2,6 years, 49 patients without MS with different neurological diseases of the control group and 52 patients diagnosed with "confirmed MS" in the remission stage who were not treated with disease-modifying drugs. " 08/01/2003 - "Three randomized, double-blind, placebo-controlled trials have shown that glatiramer acetate (GA) is effective in reducing relapse rate in patients with relapsing-remitting (RR) multiple sclerosis (MS). "
2.	Relapsing-Remitting Multiple Sclerosis 09/20/2012 - "In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo. " 05/01/2007 - "Glatiramer acetate (GA) is effective in reducing clinical and magnetic resonance imaging (MRI) activity in relapsing-remitting multiple sclerosis (RRMS). " 01/01/2009 - "The current study was conducted to evaluate the efficacy of glatiramer acetate (GA), an immunomodulatory drug approved for the treatment of relapsing remitting multiple sclerosis, in preventing the death of C57Bl/6J mice infected with Plasmodium berghei ANKA. " 03/20/2007 - "To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing-remitting multiple sclerosis. " 05/01/2008 - "To evaluate the safety and efficacy of long-term glatiramer acetate (GA) therapy, 46 patients with relapsing-remitting multiple sclerosis (RRMS) were treated for up to 22 years in an ongoing, open-label study. "
3.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/1997 - "Copolymer 1 (Cop-1) is a synthetic amino acid copolymer effective in suppression of experimental allergic encephalomyelitis (EAE). " 04/01/1996 - "Copolymer 1 is a synthetic amino acid copolymer, effective in suppression of experimental allergic encephalomyelitis (EAE) induced in a variety of species. " 05/01/2011 - "While earlier studies primarily attributed its clinical effect to a shift in the cytokine secretion of CD4+ T helper (T(h)) cells, growing evidence in MS and its animal model, experimental autoimmune encephalomyelitis (EAE), suggests that glatiramer acetate treatment is associated with a broader immunomodulatory effect on cells of both the innate and adaptive immune system. " 12/01/2004 - "Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies." 04/01/1996 - "Laboratory studies have shown that copolymer 1 prevents or modifies experimental allergic encephalomyelitis in several mammalian species. "
4.	Disease Progression 10/01/2009 - "Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial." 09/01/2009 - "This evaluation suggests that IFN Beta-1a SC injection, IFN Beta-1b SC injection, and glatiramer acetate represent the most cost-effective DMDs for the treatment of RRMS, where cost-effectiveness is defined as cost per relapse avoided, assuming that (a) the RRR in relapses and disease progression steps calculated from multiple DMD placebo-controlled clinical trials reflect real differences among DMDs over 2 years; and (b) resource unit costs derived from published sources reflect economic consequences of relapses and disease progression." 09/01/2010 - "There is published experience on the use of first-line disease modifying therapies in children with MS. However, about 1/3 of paediatric MS cases do not respond to IFN-beta or glatiramer acetate and continue to develop relapses and disease progression. " 11/01/2005 - "The disease-modifying treatments, IFN-beta and glatiramer acetate, have been widely available over the last decade and have shown a beneficial effect on relapse rate and magnetic resonance imaging parameters of disease activity; however, their effect on disease progression and disability is modest. " 01/01/2004 - "Glatiramer acetate did not show any significant effect on disease progression, measured as a sustained worsening in the Expanded Disability Status Scale (EDSS). "
5.	Fatigue 01/01/2008 - "Treatment with glatiramer acetate was associated with a significant improvement in fatigue symptoms and a marked reduction in absence from work. " 07/01/2004 - "Logistic regression analysis confirmed the association between glatiramer acetate use and improved fatigue, after accounting for baseline group differences. " 01/01/2008 - "The objective of this prospective naturalistic study was to evaluate the impact of glatiramer acetate on fatigue and work absenteeism. " 11/01/2002 - "Some recent studies suggest the positive effects of drugs on fatigue may be via reducing the inflammatory activity, such as for glatiramer acetate." 08/01/2014 - "Observational studies of up to 12 months duration showed that glatiramer acetate (GA) treatment of relapsing-remitting multiple sclerosis may result in decreased fatigue and improves health-related quality of life (HRQoL), with no changes in disability or mood. "

Related Drugs and Biologics

1.	copolymer 1 (glatiramer acetate)
2.	Interferon-beta
3.	Interferons
4.	Mitoxantrone (Novantrone)
5.	Amino Acids
6.	natalizumab (Tysabri)
7.	interferon beta-1b (Betaseron)
8.	Minocycline (Cyclops)
9.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
10.	HLA-DR2 Antigen (HLA DR2 Antigen)

Related Therapies and Procedures

1.	Immunomodulation
2.	Injections
3.	Immunotherapy
4.	Lasers (Laser)
5.	Subcutaneous Injections